Brainstorm Cell Therapeutics Inc. BCLI

BCLI Company Overview

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a U.S.-based biotechnology company focused on developing autologous adult stem cell therapies for neurodegenerative diseases. The company’s primary focus has been the development of NurOwn®, an investigational cell therapy platform designed to use mesenchymal stem cells (MSCs) engineered to secrete neurotrophic factors intended to support neuronal survival and modulate neuroinflammation. Brainstorm has primarily operated within the biotechnology, regenerative medicine, and central nervous system (CNS) therapeutic sectors, with a particular emphasis on amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative disorders.

The company was founded in 2000 and has evolved from an early-stage stem cell research organization into a clinical-stage biotechnology company pursuing regulatory pathways for advanced cell therapies. Brainstorm’s strategic positioning has centered on proprietary stem cell manufacturing and neurotrophic factor technology, with the company seeking differentiation through personalized autologous treatment approaches. Its development efforts have historically focused on patients with ALS, while the company has also evaluated broader neurological applications for its platform technology.